Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: AbbVie is conducting a Phase 2 multicenter, randomized study titled A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis. The study aims to evaluate the efficacy and safety of targeted therapies, specifically risankizumab and lutikizumab, for treating active psoriatic arthritis, a condition characterized by joint pain and swelling due to immune system attacks on healthy cells.
Intervention/Treatment: The study tests two drugs, risankizumab and lutikizumab, both administered via subcutaneous injection. Participants are divided into three groups: one receiving risankizumab monotherapy, another receiving lutikizumab monotherapy, and a third group receiving a combination of both drugs.
Study Design: This interventional study employs a randomized, parallel assignment model with no masking, focusing primarily on treatment. Participants are randomly assigned to one of the three treatment arms to assess the changes in disease symptoms.
Study Timeline: The study began on April 11, 2025, with an estimated primary completion and overall completion date yet to be announced. The last update was submitted on July 14, 2025, indicating ongoing recruitment and study activities.
Market Implications: This study could significantly impact AbbVie’s stock performance and investor sentiment, as successful results may enhance the company’s portfolio in the competitive field of psoriatic arthritis treatments. Investors should monitor updates closely, considering the potential influence on market dynamics and competitor positioning.
The study is currently ongoing, with further details available on the ClinicalTrials portal.